[Genetic aspects of valvulopathies].

Florence Kyndt(Inserm), Vincent Probst(Centre National de la Recherche Scientifique), Solena Le Scouarnec(Institut du Thorax), Jean‐Jacques Schott(Centre National de la Recherche Scientifique), Jean‐Noël Trochu, V. Jousseaume, André Chaventré(Centre National de la Recherche Scientifique), P. Jaafar(Centre National de la Recherche Scientifique), Hervé Le Marec(Centre National de la Recherche Scientifique), Antoine Legendre(Université de Tours), J.-P. Gueffet

PubMed

December 1, 2007

Cited by 9

Related Papers

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies

|Heart Rhythm|2011|1.5k

Congenital Heart Disease Caused by Mutations in the Transcription Factor <i>NKX2-5</i>

|Science|1998|1.3k

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2020|1.2k

Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death

|Nature|2003|961

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)

|EP Europace|2011|904